Key Safety Differentiators No IGF-1 elevation: AOD-9604 does not stimulate IGF-1, meaning it avoids risks such as organ/tissue overgrowth or acromegaly No glucose disruption: Clinical data shows it does not impair insulin sensitivity or worsen blood sugar regulation Comparable to placebo: In obesity trials, the incidence of adverse effects was similar to placebo groups, underscoring its tolerability Legal Status of AOD-9604 United States: AOD-9604 is not FDA-approved as a drug, dietary supplement, or weight loss therapy
Vestbo J, Anderson JA, Calverley PMA, et al
pancreatitis risk
Median gap between entries: 141 days Based on 19 repeat reporters Share Your Experience Rate Dihexa in the PeptIQ app and help the community make informed decisions
Eli Lillys daily anti-obesity pill orforglipron appears to be as good at spurring weight loss and lowering blood sugar in diabetes patients as popular injectable GLP-1 drugs like Ozempic, according to new data from a Phase 3 trial
Our formula is 100% plant-based and its done a great job on your skin complexion.
